



# Russia St. Petersburg Regional Chapter Annual Report - 2016

**President**

Alexey Kolbin; MD, PhD, Doctor of Science; Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; Professor of the Department of Pharmacology, Faculty of Medicine St. Petersburg State University; e-mail: alex.kolbin@mail.ru; 18599

**President-Elect****Past President****Secretary**

Alexey Kurilev, MD, Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; e-mail: alexey-kurilev@yandex.ru

**Treasurer**

Alexey Kurilev, MD, Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; e-mail: alexey-kurilev@yandex.ru

**Director**

Dmitry Belousov, DrPH, MD, CEO of Center for Pharmacoeconomics Research; e-mail: clinvest@mail.ru

**When are elections held for your Chapter's Board?  
Please indicate month and year of your last election.**

09/01/2016

**# Regional Chapter members**

14

**# Full ISPOR members**

6

**Collect membership dues or fees from individuals?**

No

**Annual dues?**

**Chapter benefits**

**Chapter's accomplishments in 2016 with regard to membership recruitment, retention, and engagement**

**Chapter's accomplishments in 2016 with regard to education and training**

Doctoral thesis on "The pharmacoeconomic evaluation of the effectiveness of chemotherapy in cancer care system".  
Andrey Pavlysh, MD, PhD, Doctor of Science, Oncology Institute; 05/04/2016, Saint-Petersburg, Russia.



## Russia St. Petersburg Regional Chapter Annual Report - 2016

### Chapter's accomplishments in 2016 with regard to research

1. Brentuximab vedotin in therapy of the recurred or refractory CD30+ systematic anaplastic large cell lymphoma in group of adult patients. *Clinical pharmacology and therapy*. 2016;25 (2):91-96. A. Kolbin, I. Vilum, M. Proskurin, Yu. Balykina
2. Economical analysis of Lixisenatide in patients with diabetes mellitus type 2. *Good Clinical Practice*. 2015; 4:53-64. A. Kolbin, A. Mosikian, A. Kurilev, Yu. Balykina, M. Proskurin, V.Chgao
3. Pharmacoeconomic analysis of Telavancin use in in Russian healthcare system for treatment of patients with nosocomial pneumonia. *Pharmacoeconomic: theory and practice*. 2016;4(2):88-92. A. Kolbin, I. Vilum, M. Proskurin, Y. Balykina
4. Pharmacoeconomic analysis of Telavancin use in in Russian healthcare system for treatment of patients with complicated skin and soft tissues infections. *Pharmacoeconomic: theory and practice*. 2016;4(2):75-81. A. Kolbin, I. Vilum, M. Proskurin, Y. Balykina
5. Mathematical model of reimbursement decision making in Russia. *Results of VIM List for 2016. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology*. 2016; 1:34-38. A. Kolbin, A. Prasolov, E. Maksimkina, Y.Balykina, Z. Golant, Y. Polushin, A. Kurylev, I. Vilum
6. Comparative clinicoepidemiological analysis of diabetes type 1 outcomes among patients with insulin glargine or degludec as a part basis-bolus treatment. *Pharmacoeconomics: theory and practice*. 2016; 4(1):1-5. A.Kolbin V.Chzhao, A.Kurylev, Y. Balykina, M. Proskurin
7. Comparative clinical and economic analysis of the outcomes of type 1 diabetes mellitus (T2DM) treated with Insulin glargine or insulin degludec as a part basis-bolus therapy. *Pharmacoeconomics: theory and practice*. 2016;4(1):209. A.Kolbin, V.Chzhao, A.Kurylev, Y. Balykina, M. Proskurin
8. Comparative clinical and economic analysis of the outcomes of type 2 diabetes mellitus (T2DM) treated with Insulin glargine or Insulin degludec in combination with oral antidiabetic agents (OAD). *Pharmacoeconomics: theory and practice*. 2016;4(1):211. A.Kolbin, V.Chzhao, A.Mosikian, A. Kurylev, Y. Balykina, M. Proskurin
9. National guidelines of using drugs (formulary system). Edition XVII, M.:Vidoks, 2016.- 1045 p. Authors, edited A.G.Chuchalina
10. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. EV0342 ePoster Viewing Resistance surveillance & epidemiology: Gram-negatives. ECCMID, 2016. A. Kolbin, R. Lawson, A. Kurylev, K. Ryan, M. Arepeva, Y. Balykina, A. Spiridonova, N.Mukhina, S.



## Russia St. Petersburg Regional Chapter Annual Report - 2016

Sidorenko 11. Pharmacoeconomic analysis of treatment among patients with severe uncontrolled asthma in Russia. *Practical pulmonology*. 2015;4:10-17. A. Kolbin, M. Frolov, T. Galankin 12. Analysis of compilation of the restrictive inventories in the Russian Federation as exemplified with "Vital essential and Indispensable Drugs" (VEID): the role of Pharmacoeconomics. *HIV-infection and immunosuppression*. 2016;8(2):71-77. A.Kolbin, A. Prasolov, E. Maksimkina, Y.Balykina, Z. Golant, Y.Polushin, A. Kurylev, I. Vilum 13. Pharmacoeconomic analysis of omalizumab therapy among children with severe uncontrolled asthma: data from real clinical practice in Russia. *Pediatric Pharmacology*. 2016;13(4):345-354. A.Kolbin, L. Namazova-Baranova, E. Vishneva, et al. 14. Development of a Search Engine for the MEDLINE Database with Search Results Ranking from the Perspective of Evidence-Based Medicine. *Value in health*. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRM69.- A369. A.Kolbin, M.Kamalov, Y.Balykina, V.Dobrynin, E.Verbitskaya. 15. Parametric and non-parametric approaches for predicting bacterial resistance. *Value in health*. ISPOR 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PHP15.-A441. M. Arepyeva, A. Kolbin, A.Kurylev, Yu. Balykina, A. Spiridonova, N. Mukhina, S. Sidorenko 16. Development of Predictive Models for the Analysis of the List of Vital Essential and Necessary Drugs Compilation. *Value in health*. ISPOR 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PHP50.-A448. A.Kolbin, A.Prasolov, Y. Balykina, E.Maksimkina, Z. Golant, Y.Polushin, A.Kurylev, I.Vilum 17. Pharmacoeconomic analysis of treatment of adult patients with severe uncontrolled asthma with omalizumab in Russia. *Value in health*. ISPOR 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRS38.-A555. A.Kolbin, M. Frolov, T.Galankin 18. Pharmacoeconomic analysis of treatment of children with severe uncontrolled asthma with omalizumab in Russia. *Value in health*. ISPOR 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRS37.-A555. A.Kolbin, L. Namazova-Baranova, E. Vishneva, M.Frolov, T. Galankin, A. Alekseeva, E.Dobrynina 19. Low-density lipoprotein cholesterol lowering efficacy of evolocumab may reduce need for apheresis in heterozygous familial hypercholesterolaemia patients according to the Russian guidelines. *Value in Health*. ISPOR 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PCV101.-A654. T.Gonzalez, A.Kurylev, A.Kolbin, T.Zinina,



## Russia St. Petersburg Regional Chapter Annual Report - 2016

Sidelnikov, G.Villa 20. Prognostic model of bacterial resistance based on the relationship between antibiotics resistance and consumption. *Clinical Microbiology and Antimicrobial Chemotherapy*. 2016;18(3):200-211.M. Arepeva, A. Kolbin, S. Sidorenko, A. Kurylev, Y. Balykina, N. Mukhina, A. Spiridonova 21. Cost of additional effectiveness of antineoplastic drugs (according to restrictive lists). *Remedium*. 2016;11:42-46. A. Kolbin, E. Maksimkina, A. Kurylev 22. Health economic assessment of antirheumatoid drugs in patients with rheumatoid arthritis progressed after methotrexate. *Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology*. 2016;9(3):20-28. A.Kolbin, A.Kurylev, M. Proskurin, Y.Balykina 23. Pharmacoeconomic aspects of Levodopa-Carbidopa Intestinal Gel in Advanced Stages of Parkinson's Disease. *Medical technology. Assessment and choice*. 2016;1(23):74-79. A.Rudakova, A.Skoromets, A.Timofeev 24. Socioeconomic outcomes of alcoholism in Russia and possible ways to reduce negative consequences. *Narcology*. 2016;15(170):49-58. L.Popovich, E.Potapchik E, Rudakova A. 25. Effectiveness of expenditure for nalaprevir in hepatitis C therapy (genotype 1) among naive patients and patients with relapse. *Journal of infectology*. 2016;3:122-125. D.Gusev, A.Rudakova, A.Uskov, L.Konovalova, Y.Lobzin 26. Analysis of vaccination effectiveness among adult patients against flu. *Medicine of extreme situations*. 2016; 2(56):25-29. A.Rudakova, S.Harith, A.Uskov, Y. Lobzin 27. Expensiveness of expenditure for second protease inhibitors hepatitis C therapy (genotype 1) among naive patients and patients with relapse. *Journal of infectology*. 2016;1:79-82. A.Rudakova, D.Gusev, A.Uskov, L.Konovalova, Y. Lobzin 28. Fixed combination of Calcipotriol and Betamethasone In psoriasis therapy: analysis of data base. *Clinical Dermatology and Venerology*. 2016;15(2): 85-90. A.Rudakova, A.Lvov 29. Dipeptidylpeptidase-4 inhibitors in diabetes type 2 therapy. *Coll. research papers XI International Scientific Congress "Rational pharmacotherapy" .- SPb.: Publishing house SPbGEU, 2016:131-132. A.Rudakova 30. Budget impact analysis of antiplatelet therapy with Ticagrelor and Clopidogrel in patients with acute coronal syndrome after coronary artery bypass surgery. *Therapeutic Archives*. 2016;88:39-49. S.Zyryanov, D. Belousov, E.Afanasyeva, E. Dumchenko 31. Pharmacoeconomic efficacy of Insulin in combination with Vildagliptin in patients with type 2 diabetes. *Clinical Pharmacology and Therapy*. 2016;*



## Russia St. Petersburg Regional Chapter Annual Report - 2016

25(4):92-96. S. Zyryanov, I. Dyakov 32. Pharmacoeconomic assessment of urinary tract infections in infants born to mothers with pathological pregnancy. Kuban Research Medical Gazette. 2016;2 (157):156-160. O.Shulakova, K.Gurevich, S.Zyryanov 33. Pharmacoeconomic analysis of drugs: What is important for physician? Effective pharmacotherapy. 2016;11:40-45. S.Zyryanov, Z.Galeeva 34. The economic prognosis of the new analogue of insulin glargine usage in diabetes mellitus type 2. Good Clinical Practice. 2016;2:5-13. D.Belousov, E.Afanasyeva 35. Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia. Good Clinical Practice. 2016;2:14-23. S.Zyryanov, D.Belousov, A. Cheberda 36. Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke. Good Clinical Practice. 2016;2:29-37. A.Cheberda, D.Belousov, A. Bogolepova 37. Clinical-economic analysis of valproate microsphere form in focal epilepsy in adults (real world evidences). Good Clinical Practice. 2016;1:4-13. D.Belousov, L.Bistritskaya, E.Afanasyeva 38. Comparative pharmacoeconomic analysis of Paclical® and Taxol® in the Russian Federation. Good Clinical Practice. 2016;1:14-24. A.Cheberda, D.Belousov 39. Comparative pharmacoepidemiological study of antihyperglycemic drugs utilization by patients with type 2 diabetes mellitus in Moscow. Diabetes Mellitus. 2016;19(3):260-272 M.Kalashnikova, D.Belousov, M.Kantemirova, M.Antsiferov 40. Comparative pharmacoeconomic analysis of oxycodone/naloxone combination analgesic and fentanyl transdermal delivery system. Good clinical practice. 2016. – 3. – in print. A.Cheberda, D.Belousov 41. Pharmacoeconomic analysis of Actemra® as second-line treatment for rheumatoid arthritis resistant to first-line biological therapy, and as first-line treatment. Good clinical practice. 2016. – 3. – in print. S.Zyryanov, A.Cheberda, D. Belousov 42. Pharmacoeconomic analysis of Perchloson® for treatment of multidrug-resistant tuberculosis. Good clinical practice. 2016. – 3. – in print. D.Belousov, A.Cheberda 43. Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome. Good clinical practice. 2016. – 3. – in print. S.Zyryanov, E.Dumchenko



# Russia St. Petersburg Regional Chapter Annual Report - 2016

## Chapter's accomplishments in 2016 with regard to policy-related activities

## Chapter's accomplishments with regard to Chapter meetings, workshops, or conferences

1. Modelling the inclusion of drugs in the Russian government reimbursement lists. This research has been presented to the Federal Ministry of Health. 2. Conducting the pharmacoepidemiology research for the State Insurance Fund on using antibiotics in state hospitals in Saint-Petersburg, Russia.

Oral and Poster Presentations at the ISPOR International and European Meeting: 1. ISPOR 19th Annual European Congress. Development of a Search Engine for the MEDLINE Database with Search Results Ranking from the Perspective of Evidence-Based Medicine. 2016, Vienna, Austria. 2. ISPOR 19th Annual European Congress. Parametric and non-parametric approaches for predicting bacterial resistance. 2016, Vienna, Austria. 3. ISPOR 19th Annual European Congress. Development of Predictive Models for the Analysis of the List of Vital Essential and Necessary Drugs Compilation. 2016, Vienna, Austria. 4. ISPOR 19th Annual European Congress.

Pharmacoeconomic analysis of treatment of adult patients with severe uncontrolled asthma with omalizumab in Russia. 2016, Vienna, Austria. 5. ISPOR 19th Annual European Congress. Pharmacoeconomic analysis of treatment of children with severe uncontrolled asthma with omalizumab in Russia. 2016, Vienna, Austria. 6. ISPOR 19th Annual European Congress. Low-density lipoprotein cholesterol lowering efficacy of evolocumab may reduce need for apheresis in heterozygous familial hypercholesterolaemia patients according to Russian guidelines. 2016, Vienna, Austria. 7. ISPOR 19th Annual European Congress. The cost of additional effectiveness of anticancer drugs according to the restrictive lists of Russia. 2016, Vienna, Austria. Oral Presentations at the Russian Meeting on health economics and health technology assessment researches:

1. 4th International science and practice symposium «HIV-medicine and pharmacoeconomic. Economic questions in HIV epidemiology, prophylaxis, diagnostics and clinic». Saint-Petersburg Health Care Committee. Analysis of restrictive lists compilation in Russian Federation on the example of restricted list. Role of Pharmacoeconomics. Saint-Petersburg 2. Therapy access: from recommendations to real practice. New opportunities of curing patients with severe uncontrolled asthma. Ministry of Health. Pharmacoeconomic aspects of the use of omalizumab in patients with severe asthma. Moscow 3. XXIII National Russian congress "Human and medicine" Ministry of Health. Systemic antimicrobials: who, when, what, how



## Russia St. Petersburg Regional Chapter Annual Report - 2016

much? Moscow 4. RUSSIAN CONFERENCE «ACTUAL QUESTIONS OF CLINICAL PHARMACOLOGY AND DRUGS SUPPORT». Ministry of Health. Simulation incorporating drugs into dosage lists. Pyatigorsk 5. IV Russian conference "Actual questions of preclinical and clinical trials of drugs and medical products". Ministry of Health. Choosing generic drugs based on HTA. The role of the observational study. Saint-Petersburg 6. Russian-Chinese scientific and practical conference on medical microbiology and clinical mycology. XIX Kashkinskie chtenia. Russian Ministry of Health. Pharmacoepidemiology of antibiotics in perinatology. Saint-Petersburg 7. Scientific and practical conference on Diabetes – social and economic burden. Saint-Petersburg Ministry of Health. Pharmacoeconomic modeling based on real clinical practice (diabetes). Saint-Petersburg 8. Discussion committee «Pharmacoeconomic analysis of breast cancer». Russian Ministry of Health. Who or what could influence on route of drug administration? (physician, patient or government). Sochi 9. Saint-Petersburg septic forum. Saint-Petersburg Ministry of Health. Pharmacoepidemiology of antibiotics in neonatology. Saint-Petersburg 10. XI International scientific congress "Rational pharmacotherapy". Russian Ministry of Health. Pharmacoepidemiology of antibiotics in Saint-Petersburg – «from children to adult». Saint-Petersburg 11. XI International scientific congress "Rational pharmacotherapy". Russian Ministry of Health. Experience of algorithm development of clinical trials ranking according to the level of their conclusiveness. Saint-Petersburg 12. Scientific and practical international conference «HIV-infection and immunosuppression. HIV-associated severe and comorbid conditions. Epidemiology and modern strategies». VIII Vinogradovskie Chtenia. Russian Ministry of Health, Russian Scientific Academy. Selection of generic drugs based on health care technology assessment. Saint-Petersburg 13. RUSSIAN CONFERENCE ON «ACTUAL QUESTIONS OF CLINICAL ONCOLOGY ». Profile Committee of the Russian Ministry of Health specialty "oncology" State Organization "Russian Scientific Centre of Oncology. N.N. Blokhin" of the Russian Ministry of Health "Russian Association of Oncologists". Cost of additional effectiveness of anticancer agents. Moscow 14. II Russian conference with international participation. "Perinatal medicine: from pregravid preparation to healthy mother care and childhood". Saint-Petersburg Healthcare Committee. Pharmacoeconomic aspects of



## Russia St. Petersburg Regional Chapter Annual Report - 2016

vicarious surfactant therapy of premature infants with respiratory distress syndrome. Saint-Petersburg 15. XXVIII Summary scientific practical conference «Actual questions of infectious diseases among children-2016». Saint-Petersburg Healthcare Committee. Pharmacoeconomic aspects of prophylaxis and therapy of infectious diseases. Saint-Petersburg 16. II nd International oncology forum «White nights». Saint-Petersburg Healthcare Committee. Pharmacoeconomic aspects of metastatic melanoma therapy. Saint-Petersburg 17. XI international scientific congress «Rational pharmacotherapy». Saint-Petersburg Healthcare Committee. Pharmacoeconomic aspects of the use of inhibitors of dipeptidyl peptidase 4 types for type 2 diabetes mellitus treatment. Saint-Petersburg 18. Scientific and practical international conference «HIV-infection and immunosuppression. HIV-associated severe and comorbid conditions. Epidemiology and modern strategies». Healthcare Committee. Pharmacoeconomics of HIV – infection therapy. Saint-Petersburg 19. Russian conference with international participation «Innovation technologies in psychiatry» in memory of academic RSA M.I. Perelman. Russian Science Academy. Pharmaeconomic aspects of tuberculosis pathogen drug susceptibility by phenotypic methods. Moscow 20. As a section of II-nd International oncology forum “White Nights -2016”. Russian Ministry of Health, The Association of Oncologists of Russia, Petrov Federal Research Institute Of Oncology. ABC/VEN-analysis in oncology: results and prospects. Saint-Petersburg 21. 11th international scientific congress «Rational Pharmacotherapy». Healthcare Committee of Saint Petersburg, Regional NGO “Professional medical Association of clinical pharmacologists of Saint Petersburg”. Pharmacoeconomic aspects of using Perampanel for treatment of drug-resistant epilepsy.

### **Chapter member's accomplishments, including articles of note or awards**

**Describe any regional patient engagement activities**

**Describe any activities organized for students or new professionals**

**Chapter Affiliations**

The First Pavlov State Medical University of St. Petersburg; St. Petersburg State University. Most of Chapter members work in these universities.

**Sponsorship Agreements**

**Formal comments to governments or health authorities**





# Russia St. Petersburg Regional Chapter Annual Report - 2016

## Input to national or regional HTA activities

1. Modelling the inclusion of drugs in the Russian government reimbursement lists. This research has been presented to the Federal Ministry of Health. 2. Conducting the pharmacoepidemiology research for the State Insurance Fund on using antibiotics in state hospitals in Saint-Petersburg, Russia.

## Committees or special interest groups

Student, Research

## Registered with regional authorities

No

## Chapter's main goals for 2017

In the spring of 2017 three events are planned: 1.HTA symposium is planned within the framework of the "XXI ANNUAL SCIENTIFIC SESSION OF THE INSTITUTE OF PHARMACOLOGY" conference. The symposium is called "Actual Problems of Health Technology Assessment". The symposium will consist of 6 oral presentations. The organizer is Saint Petersburg Medical University. The conference is to be on January 27, 2017. Saint-Petersburg, Russia. 2.HTA symposium is planned within the framework of the "Rational pharmacotherapy in Physician Practices" conference. The symposium is called "Choosing Generic on the Basis of the Principles of the HTA". The symposium will consist of 3 oral presentations. The organizer is Health Committee of Saint Petersburg. The conference is to be on February 18, 2017. Saint-Petersburg, Russia. 3.HTA symposium is planned within the framework of the "Safety of Drugs" conference. The symposium is called "Current Drug Safety Issues in Health Technology Assessment". The symposium will consist of 3 oral presentations. The organizer is Health Committee of Saint Petersburg. The conference is to take place on 24 - 25 March, 2017. Saint-Petersburg, Russia.

## 3 challenges the Chapter is facing at the start of 2017

1

It is difficult to publish Pharmacoeconomic studies from Russia in international journals.

2

Increasing the share of generics in the drug market.

3

Risk reduction in the role of HTA in decision-making authorities.

## Prepared this report

Professor Alexey Kolbin, MD, PhD, Doctor of Science  
Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; Professor of the Department of Pharmacology, Faculty of Medicine St. Petersburg State University 6 – 8 Lva Tolstogo, St. Petersburg, Russia, 197022 Tel: +79217590449 e-mail: alex.kolbin@mail.ru